1 / 12

Towards the future: medicines and the elimination of malaria

Join Timothy N.C. Wells, Chief Scientific Officer of MMV, in the fight against malaria - the leading cause of child mortality, with 800,000 deaths annually, especially in children under five. Learn about MMV's non-profit work since 1999 in Geneva to discover, develop, and deliver safe antimalarials, with a focus on pregnant women and children. Explore the latest advancements in antimalarial medicines, including new child-friendly formulations and strategies to combat resistance and severe malaria. Discover how the collaborative efforts of MMV and partners are driving the development of innovative treatments for malaria eradication. Together, we can make a difference for future generations.

derosa
Download Presentation

Towards the future: medicines and the elimination of malaria

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Towards the future: medicines and the elimination of malaria Defeating Malaria Together Timothy N.C. Wells PhD ScD Chief Scientific Officer MMV

  2. Malaria: Leading cause of child mortality 800,000 deaths: 85% in children under five Selectively targets pregnant women 225 million cases per year Half the world’s population at risk

  3. MMV at a glance • Non-profit ‘product development partnership’ established 1999 in Geneva • Mission: Discover, Develop and Deliver safe and effective antimalarials • Two products launched, two products submitted • Largest-ever pipeline of antimalarial drugs with over 50 projects from Discovery to Registration • Funded by Foundations, Governments, Companies, Individuals

  4. Changing the landscape: ACTs available to all 71% Millions of treatments 25% Coartem-D (Novartis)has treated 65 million children so far 150 million treatments of fixed dose ACTs delivered in 2010

  5. Adult medicines for un-complicated malaria • Resistance is a fact of life • Not all medicines work in all populations • Different risk-benefit profiles – allows choice • DHA-piperaquine (sigma-tau) • EMA decision expected August 2011 • Pyronaridine-artesunate (Shin-Poong) • EMA decision expected 1Q’2012 Draft Draft

  6. New child friendly medicines Pyronaridine-artesunate granule formulation – submission early 2012 DHA-piperaquine: taste-masked dispersible formulation - submission late 2012 Coartem-D: child-friendly formulation: extend to available < 5kg babies

  7. Severe Malaria Aquamat artesunate superior to quinine: 5000 patient study Guilin first prequalified (Dec 2010) with MMV’s support Only Chinese manufacturer with WHO approval Cost: approximately $1 per vial

  8. Protecting expectant mothers • Neither azithromycin nor chloroquine are optimal on their own • Synergy: azithromycin blocks chloroquine resistance clinically • 60% of mothers have bacterial infections (STI): impact on peri-natal mortality • Both drugs treat both diseases • New fixed dose formulation (Pfizer)

  9. Stopping the relapses from P vivax • 100 million patients annually • Hypnozoites: relapse without reinfection • Gold standard: Primaquine 14 days, G6PD liability • Tafenoquine (WRAIR, GlaxoSmithKline) • Pivotal Phase II/III starts 2Q 2011 • Single dose • Efficacy • Safety P. falcip. P. vivax mixed Anaemia RDS Coma Multiple Thanks to Ric Price

  10. OZ439 collaboration: MMV, Monash, Basel and Nebraska Same warhead, different scaffold High plasma concentration 48–72 h Active in ‘resistant malaria’? Currently being tested in patients (phase IIa) Powering the single dose cure: OZ439 artesunate OZ-439

  11. New medicines driving eradication Efficacy: No cross resistance or resistance induction, fast killing Safe: High therapeutic margin; no serious toxicity Long time above the IC90 in plasma Low predicted human dose Transmission-blocking Relapse- blocking Chemoprevention

  12. Thanks to all our colleagues and partners – but especially to the children and their families who make the next generation of malaria therapy a reality

More Related